Pathway to a Universal Influenza Vaccine

This event is closed. If you have any questions, please contact the planner directly.

 

NIAID is convening a scientific agenda-setting meeting to reshape our approach to universal influenza vaccine development. Specifically, NIAID seeks to identify gaps in knowledge critical to the development of universal influenza vaccines and propose research strategies to address these gaps. Ultimately, this will lead to a new strategic plan for NIAID universal influenza vaccine research that will guide future directions for the portfolio. The need for an improved approach to influenza immunization is clear: Seasonal influenza causes significant morbidity and mortality each year and the current seasonal influenza vaccines provide, at most, 60% protection against circulating viruses. Novel influenza viruses regularly emerge and can cause pandemics associated with even higher morbidity and mortality. Thus, development of a universal influenza vaccine which is broadly protective and can be given less frequently than the current seasonal vaccine is a high priority for NIAID. 

Please note, due to space constraints this workshop is by invitation only, and invitations are not transferable.

Visitors must enter the building through the front lobby entrance on Fishers Lane after 7:00 a.m. A valid, government-issued photo ID (if you are an international visitor, your passport) must be presented to the security guards. Security screenings are required for anyone not in possession of a valid HHS badge.

Details

  • When

  • Wednesday, June 28, 2017 - Thursday, June 29, 2017
    8:00 AM - 6:15 PM
    Eastern Time

  • Where

  • 5601 Fishers Lane Conference Ctr, Grand Hall 1D13
    5601 Fishers Lane
    Rockville, Maryland 20852
    USA

Additional Information

The views expressed in written conference materials or publications and by speakers and moderators at HHS-sponsored conferences do not necessarily reflect the official policies of the Department of Health and Human Services (HHS), nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!
MSN MSN
Top